Infant Bacterial Therapeutics AB (publ) (IBT-B) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.420x

Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has a cash flow conversion efficiency ratio of -0.420x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-52.25 Million ≈ $-5.62 Million USD) by net assets (Skr124.36 Million ≈ $13.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Infant Bacterial Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IBT-B total debt and obligations for a breakdown of total debt and financial obligations.

Infant Bacterial Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
United Polyfab Gujarat Limited NSE:UNITEDPOLY	0.101x
Inovio Pharmaceuticals Inc NASDAQ:INO	2.795x
Billion Electric Co Ltd TW:3027	-0.017x
QPM Energy Ltd AU:QPM	0.164x
Yusin Holding Corp TW:4557	0.042x
Hotel Holiday Garden TW:2702	0.034x
District Metals Corp V:DMX	-0.032x
Shanghai Shibei Hi-Tech Co Ltd B SHG:900902	-0.010x

Annual Cash Flow Conversion Efficiency for Infant Bacterial Therapeutics AB (publ) (2014–2024)

The table below shows the annual cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Infant Bacterial Therapeutics AB (publ) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr170.26 Million ≈ $18.32 Million	Skr-113.13 Million ≈ $-12.17 Million	-0.664x	-100.32%
2023-12-31	Skr305.15 Million ≈ $32.84 Million	Skr-101.22 Million ≈ $-10.89 Million	-0.332x	-28.24%
2022-12-31	Skr331.71 Million ≈ $35.70 Million	Skr-85.80 Million ≈ $-9.23 Million	-0.259x	-83.79%
2021-12-31	Skr395.25 Million ≈ $42.54 Million	Skr-55.62 Million ≈ $-5.99 Million	-0.141x	-6.08%
2020-12-31	Skr440.15 Million ≈ $47.37 Million	Skr-58.39 Million ≈ $-6.28 Million	-0.133x	-31.98%
2019-12-31	Skr510.40 Million ≈ $54.93 Million	Skr-51.30 Million ≈ $-5.52 Million	-0.101x	-18.03%
2018-12-31	Skr556.72 Million ≈ $59.91 Million	Skr-47.41 Million ≈ $-5.10 Million	-0.085x	+58.75%
2017-12-31	Skr168.37 Million ≈ $18.12 Million	Skr-34.76 Million ≈ $-3.74 Million	-0.206x	+45.34%
2016-12-31	Skr105.23 Million ≈ $11.32 Million	Skr-39.75 Million ≈ $-4.28 Million	-0.378x	-65.99%
2015-12-31	Skr74.81 Million ≈ $8.05 Million	Skr-17.02 Million ≈ $-1.83 Million	-0.228x	+33.45%
2014-12-31	Skr11.03 Million ≈ $1.19 Million	Skr-3.77 Million ≈ $-405.93K	-0.342x	--

About Infant Bacterial Therapeutics AB (publ)

ST:IBT-B Sweden Biotechnology

Market Cap

$75.51 Million

Skr701.68 Million SEK

Market Cap Rank

#20276 Global

#360 in Sweden

Share Price

Skr53.90

Change (1 day)

-3.75%

52-Week Range

Skr43.45 - Skr81.50

All Time High

Skr266.00